Search results for "Supportive Care"

showing 10 items of 22 documents

Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre s…

2015

Background & Aims The role of hepatic resection for hepatocellular carcinoma (HCC) in different Barcelona Clinic Liver Cancer (BCLC) stages is controversial. We aimed at measuring the survival benefit of resection vs. non-surgical-therapies in each BCLC stage. Methods Using the ITA.LI.CA database, we identified 2090 BCLC A, B, and C HCC patients observed between 2000 and 2012: 550 underwent resection, 1046 loco-regional therapy (LRT), and 494 best supportive care (BSC). A multivariate log-logistic model was chosen to predict median survival (MS) after resection vs. MS after LRT or BSC. The results were expressed as net survival benefit of resection: (MS resection - MS LRT)/MS BSC. Resul…

Malemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularLoco-regional therapieHepatocellular carcinomaSettore MED/12 - GASTROENTEROLOGIAHepatitis C virusKaplan-Meier Estimatemedicine.disease_causeGastroenterologyCohort StudiesLiver diseaseInterquartile rangeInternal medicinemedicineHumansBest supportive care; Cirrhosis; Hepatocellular carcinoma; Liver resection; Loco-regional therapies; Survival benefit; Aged; Carcinoma Hepatocellular; Cohort Studies; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Treatment Outcome; Medicine (all); HepatologyBEST SUPPORTING CAREAgedNeoplasm StagingCirrhosiHepatologyPerformance statusLiver resectionbusiness.industryMedicine (all)CIRRHOISISCarcinomaLiver NeoplasmsHepatocellularMiddle Agedmedicine.diseasePrognosisBCLC StageTreatment OutcomeCirrhosisItalySurvival benefitHepatocellular carcinomaMultivariate AnalysisFemaleLoco-regional therapiesLiver cancerbusinessBest supportive careJournal of hepatology
researchProduct

Characteristics of advanced cancer patients who were readmitted to an acute palliative/supportive care unit

2017

Objectives: The aim of this study was to assess the characteristics of patients readmitted to an acute supportive/palliative care unit (ASPCU), the reasons for readmission, and the outcome after receiving specialistic assessment and treatment. Methods: A consecutive sample of patients was assessed for a period of 10 months. Epidemiological characteristics, including age, gender, Karnofsky level, diagnosis, caregivers, education, disease awareness, kind of admission, and anticancer treatment in the previous 30 days, were recorded, as well as hospital stay, death, and discharge at home. The principal reasons for admission were recorded. Symptom intensity and opioid doses, expressed as oral …

Malemedicine.medical_specialtyPalliative careCritical CarePain medicineSymptomDiseasePatient Readmission03 medical and health sciences0302 clinical medicineNeoplasmsEpidemiologymedicineHumans030212 general & internal medicineAgedbusiness.industryPalliative CareSymptom burdenAdvanced cancerOpioidOncologyAnticancer treatment030220 oncology & carcinogenesisEmergency medicineNeoplasmFemalebusinessReadmissionSupportive caremedicine.drugHuman
researchProduct

The effects of alcoholism and smoking on advanced cancer patients admitted to an acute supportive/palliative care unit

2016

Aim: The aim of this prospective study was to determine the characteristics and symptom burden of advanced cancer patients with alcoholism problems and smoking, who were referred to an acute palliative/supportive care unit (ASPCU) of a comprehensive cancer center. Methods: Patients’ characteristics, indications for admission, kind of admission, awareness of prognosis, and anticancer treatments were recorded. The Edmonton Symptom Assessment Scale (ESAS) was used to assess physical and psychological symptoms, and the CAGE questionnaire for the diagnosis of alcoholism. Patients were also divided in three groups: persistent smokers (PS), former smokers (FS), and non-smokers (NS). The Memorial…

Malemedicine.medical_specialtyPalliative carePain medicineSymptomUnit (housing)03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansProspective StudiesIntensive care medicineProspective cohort studyPsychiatryAgedbusiness.industryNursing researchPalliative CareSmokingSymptom burdenCancerMiddle Agedmedicine.diseaseAdvanced cancerProspective StudieAlcoholismOncology030220 oncology & carcinogenesisNeoplasmFemalebusinessSupportive care030217 neurology & neurosurgeryHumanSupportive Care in Cancer
researchProduct

Supportive care services in hemato-oncology centers: a national survey

2016

Background: In the field of hemato-oncology, there is paucity of data assessing models of integration between hemato-oncology and other partner specialties. The aim of this national survey was to gather information about the status of the integration of this kind of activity in hemato-oncologic units existing in Italy. Methods: A national telephone survey was conducted to gather information about the status of the integration of hemato-oncologic and supportive care/anesthesiological services. From the national registry of hemato-oncology units, 149 centers were contacted by phone and a dedicated doctor was identified to gather information about the center through a telephone interview. Resu…

Malemedicine.medical_specialtyPalliative carePainful procedure03 medical and health sciences0302 clinical medicineHematological malignancyPain controlNeoplasmsSurveys and QuestionnairesmedicineHumansSurveys and Questionnaire030212 general & internal medicinebusiness.industryNursing researchPalliative CareHematologyTelephone surveyOncologyTelephone interviewPalliative care.teamHematological malignancySedation030220 oncology & carcinogenesisEmergency medicineVenous acceNeoplasmNational registrybusinessSupportive careHumanSupportive Care in Cancer
researchProduct

Characteristics and care pathways of advanced cancer patients in a palliative-supportive care unit and an oncological ward.

2018

Abstract BACKGROUND: A supportive palliative care unit (SPCU) may have a positive impact on patients' care. The aim of this study was to compare the pattern of patients admitted to a specialized SPCU and to a traditional oncologic ward (OW) in a consecutive sample of advanced cancer patients. METHODS: Data on patients demographics, reasons for and kind of admission, care-giver, anticancer treatments, being on/off treatment or uncertain, origin setting, who proposed hospital admission, the use of opioids, and hospitalization were gathered. The same parameters were recorded at discharge. A follow-up was performed by phone 1 month after discharge. RESULTS: Two-hundred patients were surveyed. A…

Malemedicine.medical_specialtyPalliative caremedicine.medical_treatmentDiseaseMedical Oncology03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumans030212 general & internal medicineAgedChemotherapybusiness.industryPalliative CareAfter dischargeHospital admissionAdvanced cancer patientAdvanced cancerHospitalizationOncology030220 oncology & carcinogenesisUncontrolled painEmergencyEmergency medicineHospital admissionFemaleOff TreatmentbusinessSupportive careSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
researchProduct

Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow‐Up Survey

2020

Abstract Background Fundamental Research in Oncology and Thrombosis (FRONTLINE) is a global survey of physicians' perceptions and practice in the management of venous thromboembolism (VTE) in patients with cancer. Materials and Methods The present survey, FRONTLINE 2, follows the original FRONTLINE survey (published in The Oncologist in 2003) and provides insights into how physicians perceive risk of VTE in cancer and approach its prophylaxis and treatment. Results Between November 2015 and February 2016, 5,233 respondents participated, representing cancer physicians and surgeons. Most believed that less than one in five patients with any cancer might be at risk of VTE, with a slightly high…

OncologyCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatment26030204 cardiovascular system & hematologyFondaparinuxDabigatranVenous thromboembolism • Cancer-associated thrombosis • Deep vein thrombosis • Pulmonary embolism • Central venous catheter.03 medical and health sciences0302 clinical medicineInternal medicineSurveys and QuestionnairesVenous thromboembolism • Cancer‐associated thrombosis • Deep vein thrombosis • Pulmonary embolism • Central venous cathetermedicineHumansRivaroxabanbusiness.industryAnticoagulantWarfarinCancerAnticoagulantsThrombosisVenous ThromboembolismHeparin Low-Molecular-Weightmedicine.diseasePulmonary embolismOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisbusinessCentral venous cathetermedicine.drugFollow-Up StudiesThe Oncologist
researchProduct

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab

2020

Abstract Background & Aims Radiological progression patterns to first‐line sorafenib have been associated with post‐progression and overall survival in advanced hepatocellular carcinoma, but these associations remain unknown for therapies in second‐ and later‐line settings. This post hoc analysis of REACH and REACH‐2 examined outcomes by radiological progression patterns in the second‐line setting of patients with advanced hepatocellular carcinoma treated with ramucirumab or placebo. Methods Patients with advanced hepatocellular carcinoma, Child‐Pugh A and Eastern Cooperative Oncology Group Performance Status 0 or 1 with prior sorafenib were randomized to receive ramucirumab 8mg/kg or place…

OncologySorafenibLiver CancerMalemedicine.medical_specialtyCarcinoma HepatocellularramucirumabPopulationRadioteràpiaAntineoplastic AgentsPlaceboAntibodies Monoclonal HumanizedRamucirumabLesionCàncer de fetge03 medical and health sciencesbest supportive care0302 clinical medicineInternal medicinePost-hoc analysisMedicineHumanseducationdisease progression patternseducation.field_of_studyHepatologyRadiotherapybusiness.industryProportional hazards modelLiver NeoplasmsMiddle AgedSorafenibmedicine.diseaseTreatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyOriginal Articlemedicine.symptombusinesspost‐progression survivalnew extrahepatic lesionLiver cancermedicine.drug
researchProduct

Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials

2005

In the last two decades the results of medical treatment of advanced non-small cell lung cancer (NSCLC) have constantly improved even if they are still far from being considered satisfactory. Today systemic cisplatin-based chemotherapy (CT) is able to increase survival and improve cancer-related symptoms in patients with advanced ‘wet’ stage III and metastatic stage IV NSCLC, but it not clear if the benefits of CT also apply to patients with poor performance status (PS) [1, 2]. PS is the most powerful independent prognostic factor in advanced NSCLC since it is a reliable measure of functional independence, ability to perform daily activities and work, and a strong predictor of survival and …

Oncologymedicine.medical_specialtyLung Neoplasmsbusiness.industryDrugs Investigationallung cancer performance status 2 chemotherapy best supportive careHematologymedicine.diseaseClinical trialRegimenOncologyQuality of lifeCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansControlled Clinical Trials as TopicStage (cooking)Lung cancerbusinessAdverse effectSurvival rateSurvival analysisNeoplasm StagingAnnals of Oncology
researchProduct

European Society for Medical Oncology (ESMO) position paper on supportive and palliative care

2018

Oncology has come a long way in addressing patients' quality of life, together with developing surgical, radio-oncological and medical anticancer therapies. However, the multiple and varying needs of patients are still not beingmet adequately as part of routine cancer care. Supportive and palliative care interventions should be integrated, dynamic, personalised and based on best evidence. They should start at the time of diagnosis and continue through to end-of-life or survivorship. ESMO is committed to excellence in all aspects of oncological care during the continuum of the cancer experience. Following the 2003 ESMO stand on supportive and palliative care (Cherny N, Catane R, Kosmidis P. …

Oncologymedicine.medical_specialtyPalliative caremedia_common.quotation_subjectPatient-Centered Care/methodsPsychological interventionPatient-centred care03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Multidisciplinary approachExcellenceInternal medicineSurvivorship curveNeoplasmsPatient-Centered CaremedicineNeoplasms/therapyHumansPosition paper030212 general & internal medicinemedia_commonPalliative Care/methodsTerminal Carebusiness.industryPalliative CareCancerHematologyESMOmedicine.diseaseTerminal Care/methodsMultidisciplinarityOncology030220 oncology & carcinogenesisPractice Guidelines as TopicPalliative careQuality of LifePosition paperbusinessSupportive care
researchProduct

End-of-Life Care in High-Grade Glioma Patients. The Palliative and Supportive Perspective.

2018

High-grade gliomas (HGGs) are the most frequently diagnosed primary brain tumors. Even though it has been demonstrated that combined surgical therapy, chemotherapy, and radiotherapy improve survival, HGGs still harbor a very poor prognosis and limited overall survival. Differently from other types of primary neoplasm, HGG manifests also as a neurological disease. According to this, palliative care of HGG patients represents a peculiar challenge for healthcare providers and caregivers since it has to be directed to both general and neurological cancer symptoms. In this way, the end-of-life (EOL) phase of HGG patients appears to be like a journey through medical issues, progressive neurologic…

end of lifemedicine.medical_specialtyPalliative caremedicine.medical_treatmentPsychological interventionMEDLINEDiseaseReviewlcsh:RC321-57103 medical and health sciences0302 clinical medicineQuality of lifemedicineIntensive care medicineastrocytomalcsh:Neurosciences. Biological psychiatry. Neuropsychiatrypalliative carebusiness.industrySettore MED/27 - NeurochirurgiaGeneral NeuroscienceglioblastomaRadiation therapysupportive careDistress030220 oncology & carcinogenesisbusinessEnd-of-life care030217 neurology & neurosurgeryhigh-grade gliomaBrain sciences
researchProduct